The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RYTM | +70.92% | +251.22% | +28.56% | +216% |
| S&P | +16.53% | +80.89% | +12.59% | +167% |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
This biotech stock is flying under the radar for many investors, but Wall Street loves it.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $57.25M | 36.9% |
| Gross Profit | $52.45M | 38.5% |
| Gross Margin | 91.61% | 1.1% |
| Market Cap | $7.14B | 107.6% |
| Market Cap / Employee | $17.25M | 0.0% |
| Employees | 414 | 46.3% |
| Net Income | -$47,505.00K | -9.7% |
| EBITDA | -$46,791.00K | -14.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.30M | -39.1% |
| Accounts Receivable | $26.08M | 40.9% |
| Inventory | 25.8 | 37.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $235.19M | -7.8% |
| Short Term Debt | $7.95M | 415.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.94% | 26.8% |
| Return On Invested Capital | -63.52% | -8.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26,342.00K | -39.8% |
| Operating Free Cash Flow | -$25,389.00K | -34.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 152.09 | 211.76 | -542.02 | 47.96 | -84.36% |
| Price to Sales | 24.41 | 25.75 | 38.38 | 37.72 | 42.36% |
| Price to Tangible Book Value | 212.46 | 308.94 | -365.60 | 49.82 | -93.01% |
| Enterprise Value to EBITDA | -70.43 | -88.89 | -124.85 | -149.87 | 81.01% |
| Return on Equity | -419.0% | -1334.5% | -240.4% | -244.5% | -10.18% |
| Total Debt | $257.73M | $259.47M | $259.97M | $243.13M | -5.24% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
